Joshua A. McKeever
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua A. McKeever has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrew S. Koh
Department of Pathology, University of Chicago, Chicago, USA
45 shared publications - Anika T. Thomas-Toth
Department of Pediatrics, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois. 1
42 shared publications - James L. LaBelle
University of Chicago
42 shared publications - Jocelyn Y. Hsu
Department of Pediatrics, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois. 1
42 shared publications - Nada S. Aboelella
University of Chicago 3 Section on Hematology/Oncology, Department of Medicine Chicago, Illinois
42 shared publications - Rosy Liao
Department of Pediatrics, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois. 1
42 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S9. Tamoxifen does not alter T cell subpopulation cells or MC38 growth
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S9. Tamoxifen does not alter T cell subpopulation cells or MC38 growth
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S1. Venetoclax confers Treg-specific transcriptional alterations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S1. Venetoclax confers Treg-specific transcriptional alterations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S6. PI3K activation occurs in all T cells following venetoclax.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S6. PI3K activation occurs in all T cells following venetoclax.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S10. Percentage of RORγt+ Tregs in the (A) spleens (B) draining lymph nodes, and (C) tumors of Foxp3eGFP-Cre-ERT2 Bcl2fl/fl 7 days into treatment as shown in Fig. 7. Data represented as means ± SD. *p < 0.05, **p <0.01, ***p < 0.001.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S10. Percentage of RORγt+ Tregs in the (A) spleens (B) draining lymph nodes, and (C) tumors of Foxp3eGFP-Cre-ERT2 Bcl2fl/fl 7 days into treatment as shown in Fig. 7. Data represented as means ± SD. *p < 0.05, **p <0.01, ***p < 0.001.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S3. Effects of venetoclax on T cell numbers are reserved following 14day drug holiday.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S3. Effects of venetoclax on T cell numbers are reserved following 14day drug holiday.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S2. Venetoclax results in significant lymphodepletion in (A) lymph node and (B) spleen.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S2. Venetoclax results in significant lymphodepletion in (A) lymph node and (B) spleen.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S4. Shift in RORγt+ Tregs coexpressing IL-17A or IFNγ Representative plots of RORγt, IFNγ, and IL-17A in Tregs in spleens from mice treated with (red) and without venetoclax (blue) following 4 hours of PMA/ionomycin stimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Supplementary Figure S4. Shift in RORγt+ Tregs coexpressing IL-17A or IFNγ Representative plots of RORγt, IFNγ, and IL-17A in Tregs in spleens from mice treated with (red) and without venetoclax (blue) following 4 hours of PMA/ionomycin stimulation.